Plain-English translation of NCT07073547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which is a type of therapy that uses your own immune cells to fight multiple myeloma. The medical team will collect some of your immune cells, train them to recognize and attack cancer cells, then put them back into your body. Researchers want to understand how safe the medication is, how long it stays active in your body, and how well it works.
Multiple myeloma is a serious blood cancer, and even with current treatments, many patients still face relapse or don't respond well to therapy. This trial exists to see if this new approach — using engineered immune cells — could offer patients a more effective option.
You likely qualify if…
You likely don't qualify if…
You will receive a single infusion of the treatment at the study center. Before and after the infusion, you'll have blood tests and other evaluations to monitor your safety, how your immune system responds, and whether the treatment is working. The study will also track how the engineered cells behave in your body over time. Some participants may also receive additional supportive therapy, depending on which group you're in.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States